Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) EBT Margin (2018 - 2025)

X4 Pharmaceuticals (XFOR) has disclosed EBT Margin for 6 consecutive years, with 1690.93% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EBT Margin rose 485924.0% year-over-year to 1690.93%, compared with a TTM value of 278.44% through Sep 2025, up 120633.0%, and an annual FY2024 reading of 1428.46%, changed N/A over the prior year.
  • EBT Margin was 1690.93% for Q3 2025 at X4 Pharmaceuticals, down from 1302.79% in the prior quarter.
  • Across five years, EBT Margin topped out at 16136.94% in Q2 2024 and bottomed at 6550.18% in Q3 2024.
  • Average EBT Margin over 4 years is 1695.99%, with a median of 2143.63% recorded in 2022.
  • The sharpest move saw EBT Margin skyrocketed 1128529bps in 2024, then crashed -1743973bps in 2025.
  • Year by year, EBT Margin stood at 2542.83% in 2022, then soared by 91bps to 4851.66% in 2023, then crashed by -154bps to 2637.53% in 2024, then skyrocketed by 36bps to 1690.93% in 2025.
  • Business Quant data shows EBT Margin for XFOR at 1690.93% in Q3 2025, 1302.79% in Q2 2025, and 1.1% in Q1 2025.